Endometrial stromal sarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases

International Journal of Gynecological Cancer

Volumn 9, Issue 2, 1999, Pages 98-104

  Blom, R ^a   Malmstrom H ^a   Guerrieri, C ^a,b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Lung Transplant Unit   (United States)

Author keywords

DNA ploidy; Endometrial stromal sarcoma; mdm 2; p53

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; FLUOROURACIL; MESNA; METHOTREXATE; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; ENDOMETRIUM SARCOMA; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; UTERUS SARCOMA;

EID: 0032898669     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.09870.x     Document Type: Article

References (28)

1. Mansi JL, Ramachandra S, Wiltshaw E, Fisher C. Endometrial stromal sarcomas. Gynecol Oncol 1990; 36:113-8.
2. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 1966; 19:755-66.
3. Chang KL, Crabtree GS, Lim-Tak SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasms. A clinopathologic study of 117 cases. Am J Surg Pathol 1990; 14:415-38.
4. rd series, fascicle 3. Washington, D.C. Armed Forces Institute of Pathology.
5. Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 1982; 50:2170-82.
6. El-Naggar AK, Abdul-Karim FW, Silva EG, McLemore D, Garnsey L. Uterine stromal neoplasms: A clinicopathologic and DNA flow cytometric correlation. Hum Pathol 1991; 22:897-903.
7. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis J. Treatment of endometrial stromal tumors. Gynecol Oncol 1990; 36: 60-5.
8. El-Deiry WS, Tokino T, Velculesco VE, et al. WAF1, a potential mediator of p53 suppression, Cell 1993; 75:817-25.
9. Lane DP. P53, guardian of the genome. Nature 1992; 358:15-6.
10. Levin AJ, Pery ME, Chang A et al. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69:409-16.
11. Cordon-Cardo C, Latres E, Drobnjak M et al. Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54:794-9.
12. Chen J, Marechal V, Levine A. Mapping of the p53 and MDM2 interactions domains. Mol Cell Biol 1993; 4107-4114.
13. Momand J, Zambetti G. Mdm-2: "Big Brother" of p53. J Cell Biochem 1997; 64:343-52.
14. Malmström H, Schmidt H, Persson PG, Carstensen J, Nordenskjöld B, Simonsen E. Flow cytometry analysis of uterine sarcoma: Ploidy and S-phase rate as prognostic indicators. Gynecol Oncol 1992; 44:172-7.
15. Wolfson A, Wolfson D, Sittler S et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994; 52:56-62.
16. Kjellberg L, Boquist L, Stendahl U, Tribukait B. Flow cytometry analysis of uterine sarcomas. Gynecol Oncol 1994; 55:339-42.
17. Blom R, Guerrieri C, Stål O, Malmström H, Simonsen E. Leiomyosarcoma of the uterus: DNA flow cytometry, p53 and mdm-2 analysis of 49 cases. Gynecol Oncol 1998; 68:54-61.
18. Wingren S, Hatschek T, Stål O, Boeryd B, Nordenskjöld B. Comparison of static and flow cytofluorometry for estimation of DNA index and S-phase fraction in fresh and paraffin-embedded breast carcinoma tissue. Acta Oncol 1988; 27:793-7.
19. Hiddeman W, Schumann J, Andreeff M et al. Convention on nomenclature for DNA cytometry. Cytometry 1984; 5: 445-6.
20. Shankey TV, Rabinovitch PS, Bagwell B et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993; 14: 472-7.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Nordal RR, Kristensen GB, Kaern J et al. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996; 62: 254-9.
23. Yoonessi M, Hart WR. Endometrial stromal sarcomas. Cancer 1977; 40: 898-906.
24. De Fusco PA, Gaffey TA, Malkasian GD, Long HJ, Cha SS. Endometrial stromal sarcoma: Review of Mayo Clinic Experience, 1945-80. Gynecol Oncol 1989; 35:8-14.
25. August CZ, Bauer KD, Laurin J, Murad T. Neoplasms of endometrial stroma: Histopathologic and flow cytometric analysis with clinical correlation. Human Pathol 1989; 20:232-7.
26. Hitchcock CL, Norris HJ. Flow cytometric analysis of endometrial stromal sarcoma. Am J Clin Pathol 1992; 97:267-71.
27. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994; 83: 118-24.
28. Blom R, Guerrieri C, Stål O, Malmström H, Sullivan S, Simonsen E. Malignant mixed Müllerian tumors of the uterus: A clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 44 cases. Gynecol Oncol 1998; 68:18-24.